EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies

Alexander Philipovskiy, Scott Shurmur, Muhammad Bilal Abid

Cancers · 17.08.2026 · 18 (16) · 2652

DOI: 10.3390/cancers18162652 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.08.2026. Verfasst von Alexander Philipovskiy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center and UMC/TLC2 Cancer Center, 602 Indian…. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) have matured from a technically challenging concept into an established therapeutic platform across hematologic and solid malignancies. By linking a monoclonal antibody to a potent cytotoxic payload, ADCs seek to increase tumor-directed drug delivery while limiting systemic exposure; however, clinical performance depends on much more than target expression. Target accessibility, antigen density and heterogeneity, internalization, intracellular trafficking, linker stability, payload properties, drug-to-antibody ratio, bystander effect, tumor penetration, and host-tissue handling jointly shape efficacy and toxicity. This review provides a clinician-oriented assessment of the contemporary ADC landscape and the principal biologic and pharmacologic determinants of benefit. We discuss signature toxicities, including interstitial lung disease and ocular injury, and summarize evolving mechanisms of resistance and biomarker development. Particular emphasis is placed on three translational problems that are becoming increasingly important as ADCs move into earlier lines and overlapping disease settings: dose optimization beyond the maximum tolerated dose, sequencing across targets and payload classes, and biologically rational combination strategies. We also present a conceptual Sequential Tumor Attack Model as a hypothesis-generating framework for tumor-access priming, ADC-mediated cytotoxic injury, and immune amplification, while explicitly recognizing that the complete model has not been clinically validated. The future impact of ADCs will depend not only on next-generation constructs, but also on rigorous evidence for how these agents should be dosed, ordered, and combined in practice.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatesbiomarkerscombination strategiesdose optimizationinterstitial lung diseaselinkerpayloadresistancesequencingtranslational oncology

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Internal Medicine, Texas Tech University Health Sciences Center and UMC/TLC2 Cancer Center, 602 Indiana Ave., Lubbock, TX 79415, USA.
  • Department of Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.

Zitieren

APA

Philipovskiy, A., Shurmur, S., & Abid, M. B. (2026). Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies. Cancers, 18(16), 2652. https://doi.org/10.3390/cancers18162652

Vancouver

Philipovskiy A, Shurmur S, Abid MB. Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies. Cancers. 2026;18(16):2652. doi:10.3390/cancers18162652

BibTeX
@article{Philipovskiy2026,
  author = {Philipovskiy, Alexander and Shurmur, Scott and Abid, Muhammad Bilal},
  title = {Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2652},
  doi = {10.3390/cancers18162652}
}
Kostenlos starten →